Welcome to our dedicated page for Smith Midland SEC filings (Ticker: SMID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to locate how barrier rentals or SlenderWall royalties flow through Smith-Midland鈥檚 financials? This SEC filings hub guides you from question to answer in minutes.
What investors typically seek in Smith-Midland documents: revenue split between precast sales and rentals, licensing margins from Easi-Set technology, raw-material cost pressures, and insider buying around new DOT contracts. Those nuggets are buried across 10-Ks, 10-Qs, 8-Ks and proxy statements.
Stock Titan鈥檚 AI reads every filing the moment it posts to EDGAR and delivers:
- Plain-English highlights of each Smith-Midland quarterly earnings report 10-Q filing
- AG真人官方-time alerts for Smith-Midland Form 4 insider transactions and executive stock moves
- Context around Smith-Midland 8-K material events explained鈥攆rom plant expansions to patent awards
- Concise breakdowns of the Smith-Midland annual report 10-K simplified, including segment profitability and backlog detail
Common questions鈥斺�渦nderstanding Smith-Midland SEC documents with AI鈥� or 鈥淪mith-Midland proxy statement executive compensation鈥濃�攁re answered directly inside each summary, so you never search through footnotes again.
Whether you need Smith-Midland insider trading Form 4 transactions before earnings, a quick Smith-Midland earnings report filing analysis, or a snapshot of Smith-Midland executive stock transactions Form 4, our platform keeps you current. All filings, all form types, updated in real time and explained simply鈥攕o you can focus on interpreting the numbers, not finding them.
Smith-Midland Corporation (NASDAQ: SMID) delivered a markedly stronger first quarter of 2025, leveraging a large, high-margin barrier-rental project to lift both revenue and profitability. All figures are unaudited and expressed in thousands, except per-share data.
- Revenue jumped 35% year-over-year to $22.7 million (Q1-24: $16.8 million). The key driver was barrier rentals, which rose eight-fold to $8.4 million, offsetting a 15% slide in product sales.
- Gross profit nearly doubled to $7.0 million, expanding gross margin to 30.7% (Q1-24: 23.3%) as rental mix improved cost leverage (cost of sales fell to 72% of sales from 79%).
- Operating income advanced 191% to $4.4 million; net income climbed 190% to $3.3 million, driving basic EPS to $0.63 versus $0.22 a year ago.
- Cash increased to $9.0 million (12/31/24: $7.5 million) after generating $2.2 million of operating cash flow; long-term debt declined slightly to $4.3 million and the $5.0 million revolver remains undrawn.
- Balance sheet strength: Equity rose to $45.1 million, representing 60% of total assets. Tangible-net-worth and capital-spending covenants under bank facilities remain in compliance.
- Backlog at 5 May 2025 was $52.4 million, down 19% from $64.6 million a year earlier; management expects most projects to convert to revenue within 12 months.
- Management reiterated its strategy to expand SlenderWall sales, grow barrier-rental fleet and pursue infrastructure-linked demand; planned 2025 capex totals ~$5 million.
Operational considerations
- One customer accounted for 33% of Q1-25 revenue; two customers each represented >10% of receivables.
- A ransomware incident occurred in Q1-25 but was resolved without payment; network security changes were implemented.
- Material weaknesses in entity-level and IT controls identified in 2024 remain unremediated; a new CFO was hired and remediation efforts are under way.
Outlook: Management anticipates sustained soundwall and building demand, incremental SlenderWall orders in 2H-25 and continued emphasis on barrier rentals. However, reduced backlog, customer concentration and unresolved control weaknesses introduce execution and governance risk.
Dare Bioscience, Inc. (DARE) filed a Form 4 disclosing the grant of 4,500 non-qualified stock options to independent director Jessica D. Grossman on 07/09/2025. The options carry an exercise price of $2.44 per share and expire on 07/09/2035.
Vesting terms: The award vests in full on the earlier of (i) the first anniversary of the grant date or (ii) immediately prior to the company鈥檚 first annual shareholder meeting following the grant. Full acceleration occurs upon a change in control, provided the director remains on the board.
Post-grant holdings: Following this transaction, Dr. Grossman beneficially owns 4,500 derivative securities (stock options) and no change was reported for common shares in Table I, indicating the grant is additive rather than a sale.
Governance context: Routine equity compensation for directors aligns incentives with shareholder interests but results in a modest potential dilution of approximately 0.01% of outstanding shares, assuming ~45 million shares outstanding (company total not provided in filing). No cash was exchanged and there is no immediate earnings impact.
FAQ
What is the current stock price of Smith Midland (SMID)?
What is the market cap of Smith Midland (SMID)?
What core industries does Smith-Midland Corporation serve?
How does the company generate revenue?
What distinguishes Smith-Midland鈥檚 products in the market?
How are its manufacturing facilities strategically important?
What role do subsidiaries like Easi-Set Worldwide play?
How does Smith-Midland ensure quality and safety in its products?
What makes the company's business model robust?
